Global Raloxifene Market Size, Share and Trends Analysis Report, By Application (Osteoporosis and Breast Cancer Prevention) Forecast (2022-2028)

The global raloxifene market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Raloxifene is used to prevent and treat osteoporosis in postmenopausal women. Raloxifene also reduces the risk of invasive breast cancer in postmenopausal women. The global raloxifene market is growing due to the increasing geriatric population globally. The World Health Organization report 2021 states that between 2015 and 2050, the proportion of the world’s population over 60 years will nearly double from 12% to 22%. Owing to its high prevalence, osteoporosis is one of the diseases which is considered a serious public health concern. According to an article published by the US National Library of Medicine in December 2016, it has been estimated that more than 200 million people are suffering from osteoporosis globally. Additionally, the rising cases of breast cancer globally are directly boosting the demand for the raloxifene drug. According to the American Society of Clinical Oncology, 2.3 million new cases of breast cancer were diagnosed in women across the globe in 2020. Furthermore, several USFDA approvals for generic drugs and the adoption of new treatment procedures are anticipated to propel the growth of the global raloxifene market during the forecast period.

The global raloxifene market is segmented into osteoporosis and breast cancer prevention, based on application. The osteoporosis market is anticipated to hold the major share in the global raloxifene market. According to recent statistics provided by the International Osteoporosis Foundation, globally, 1 in 3 women over the age of 50 years and 1 in 5 men will experience osteoporotic fractures in their lifetime. Therefore, the rising prevalence of osteoporosis globally is driving the growth of the global raloxifene market.

Some major players in the market include Eli Lilly and Co., Teva Pharmaceutical Industries Ltd., Camber Pharmaceuticals, Inc., and Zydus Group among others. The market player is contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and launches, to stay competitive in the market. For instance, in October 2020, the USFDA FDA approved Evista raloxifene to prevent invasive breast cancer among postmenopausal women with osteoporosis and postmenopausal women who are at a high risk of developing breast cancer.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Eli Lilly and Co., Teva Pharmaceutical Industries Ltd., Camber Pharmaceuticals, Inc., and Zydus Group, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Raloxifene Market Report by Segment

By Application

• Osteoporosis
• Breast Cancer Prevention

Global Raloxifene Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America